Anemia Clinical Trial
Official title:
Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study
Rationale: Iron deficiency and zinc deficiency, are of public health significance in
sub-Saharan Africa. An estimated 50% of children (5-14 years) in developing countries suffer
from anaemia, half of which is estimated iron deficiency anaemia. Interventions have been
designed and implemented over the years towards solving hunger and anaemia especially among
school age children. One of such interventions is School Feeding Programme (SFP) which is
common in both developing and industrialized countries. SFP has been part of the Ghanaian
educational system for well over 40 years, albeit on small scale. The main stay of the
programme that makes it distinguishable from other past and existing school feeding
programmes is its reliance on locally produced and available foods, such as cowpeas. Legume
staples like cowpea have been identified to be important sources of protein and non-heme
iron to rural populations of developing countries like Ghana. The problem however is the low
bioavailability of these micronutrients from these legumes.
Objective: To assess the efficacy of iron fortified cowpea based meal (Tubani) in improving
iron status of primary school children in rural northern Ghana Study design: A randomized
double blind parallel design will be conducted. One group will receive iron fortified Tubani
with NaFeEDTA and the other group will receive unfortified Tubani.
Study population: Two hundred and forty apparently healthy pupils in lower primary school
will participate. The participating schools have a school feeding programme currently in
operation.
Intervention (if applicable): Children will be fed Tubani containing 10mg of fortification
iron (in the form of NaFeEDTA) three times in a week for six months. Weight, height and
blood samples will be measured at baseline and after six months of intervention.
Participants will be treated against intestinal parasites before start of intervention and
halfway through the intervention.
Main study parameters/endpoints: The main study endpoint is iron-deficiency anaemia (IDA).
IDA will be defined as concurrent anaemia and iron deficiency. Whole blood will be collected
for the analysis of Hb, serum ferritin (SF), serum transferring receptor (sTfR) and
C-reactive protein (CRP). Anemia will be defined as a hemoglobin concentration <115 g/L, and
iron deficiency will be defined as an SF concentration <12 µg/L.
Venipunctures occasionally lead to bruises or small local inflammation which usually
disappear within one week. To minimize this risk, blood collection will be performed by a
trained and experienced phlebotomists. Written informed consent will be obtained from all
subjects.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |